Browsing Tag
Personalis
3 posts
Tempus AI company profile: How diagnostics, health data and AI are building a precision medicine platform
Tempus AI, Inc. has built a precision medicine business around genomic diagnostics, multimodal health data, artificial intelligence and pharmaceutical research services. Ambry Genetics, Deep 6 AI, Paige and OneOme have widened that platform, while the proposed Personalis acquisition could bring molecular residual disease technology, laboratory economics and longitudinal cancer monitoring more tightly inside the company.
August 30, 2026
Tempus AI agrees to acquire Personalis in $1.5bn precision oncology deal built around a $46 floor price
Tempus AI to buy Personalis at $16.25 per share in a $1.5B stock-plus-optional-cash deal, with a $46 Tempus floor that gives Personalis the right to walk if breached.
July 21, 2026
Merck invests $50m in Personalis to bolster Moderna collaboration on individualized cancer therapies
Personalis, Inc., a leader in precision oncology solutions, has secured a significant investment from Merck and extended its…
December 19, 2024